Chapter
Periodontal Disease as a Clinical Trial Endpoint
1:31:35 - 1:36:05 (04:29)
Periodontal disease is a great clinical trial endpoint as it shows relatively quick effects and is non-invasive. It could lead to FDA approval if an effect is found through clinical trials.
Clips
The FDA asked a company to use patient-reported infections instead of laboratory-confirmed infections as an endpoint due to patient quality of life being prioritized.
1:31:35 - 1:32:08 (00:32)
Summary
The FDA asked a company to use patient-reported infections instead of laboratory-confirmed infections as an endpoint due to patient quality of life being prioritized.
ChapterPeriodontal Disease as a Clinical Trial Endpoint
Episode#610: The Life-Extension Episode — Dr. Matt Kaeberlein on The Dog Aging Project, Rapamycin, Metformin, Spermidine, NAD+ Precursors, Urolithin A, Acarbose, and Much More
PodcastThe Tim Ferriss Show
Rapamycin has shown potential benefits in treating periodontal disease, and a larger clinical trial could pave the way for FDA approval for this use case.
1:32:08 - 1:34:35 (02:26)
Summary
Rapamycin has shown potential benefits in treating periodontal disease, and a larger clinical trial could pave the way for FDA approval for this use case. Despite its potential, some VC's are hesitant to invest in this research.
ChapterPeriodontal Disease as a Clinical Trial Endpoint
Episode#610: The Life-Extension Episode — Dr. Matt Kaeberlein on The Dog Aging Project, Rapamycin, Metformin, Spermidine, NAD+ Precursors, Urolithin A, Acarbose, and Much More
PodcastThe Tim Ferriss Show
The top sprinters in the world were found to have narcolepsy as they tried to use modafinil as a way to get ahead in their performance.
1:34:35 - 1:36:05 (01:29)
Summary
The top sprinters in the world were found to have narcolepsy as they tried to use modafinil as a way to get ahead in their performance. Periodontal disease is a great clinical trial endpoint because it's not invasive and the effects are seen relatively quickly.